CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)

NCT03289455 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

23

Enrollment

INDUSTRY

Sponsor class

Conditions

B Acute Lymphoblastic Leukemia
Recurrent Childhood Acute Lymphoblastic Leukemia
Refractory Childhood Acute Lymphoblastic Leukemia
B-cell Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL: AUTO3 (CD19/22 CAR T cells

Sponsor

Autolus Limited